Advertisement
Screener

AVALO THERAPEUTICS, INC. (AVTX) Increase (Decrease) in Accounts Receivable

2.8 / 5 stars · 68/120 Roast Me

AVALO THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable

AVALO THERAPEUTICS, INC. (AVTX) reported Increase (Decrease) in Accounts Receivable of $0 for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-12.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2024-08-12

  • AVALO THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-12-31 was $0.00.
  • AVALO THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-09-30 was -$38.00K.
  • AVALO THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-06-30 was $38.00K.
  • AVALO THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was $0.00.
  • AVALO THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
  • AVALO THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$1.06M.
  • AVALO THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2021 was -$1.12M, a 264.75% decline from fiscal 2020.
  • AVALO THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2020 was $678.00K.
Period endIncrease (Decrease) in Accounts Receivable 3 monthIncrease (Decrease) in Accounts Receivable 3 month as first filedIncrease (Decrease) in Accounts Receivable 6 monthIncrease (Decrease) in Accounts Receivable 6 month as first filedIncrease (Decrease) in Accounts Receivable 9 monthIncrease (Decrease) in Accounts Receivable 9 month as first filedIncrease (Decrease) in Accounts Receivable 12 monthIncrease (Decrease) in Accounts Receivable 12 month as first filed
2024-06-30$0.00
10-Q · filed 2024-08-12
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
-$38.00K
derived: sum of 2 quarters · filed 2024-03-29
$0.00
derived: sum of 3 quarters · filed 2024-08-12
$0.00
10-K · filed 2024-03-29
2023-09-30-$38.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$0.00
derived: sum of 2 quarters · filed 2024-08-12
$0.00
10-Q · filed 2023-11-09
$0.00
derived: sum of 4 quarters · filed 2024-08-12
2023-06-30$38.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
$38.00K
10-Q · filed 2024-08-12
$38.00K
derived: sum of 3 quarters · filed 2024-08-12
-$506.00K
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31$0.00
10-Q · filed 2023-05-04
$0.00
derived: sum of 2 quarters · filed 2024-03-29
-$544.00K
derived: sum of 3 quarters · filed 2024-03-29
-$937.00K
derived: sum of 4 quarters · filed 2024-03-29
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
-$544.00K
derived: sum of 2 quarters · filed 2024-03-29
-$937.00K
derived: sum of 3 quarters · filed 2024-03-29
-$1.06M
10-K · filed 2024-03-29
2022-09-30-$544.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$937.00K
derived: sum of 2 quarters · filed 2023-11-09
-$1.06M
10-Q · filed 2023-11-09
-$1.44M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$393.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
-$516.00K
10-Q · filed 2023-08-03
-$891.00K
derived: sum of 3 quarters · filed 2023-08-03
-$3.58M
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31-$123.00K
10-Q · filed 2023-05-04
-$498.00K
derived: sum of 2 quarters · filed 2023-05-04
-$3.18M
derived: sum of 3 quarters · filed 2023-05-04
-$2.19M
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31-$375.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29
-$3.06M
derived: sum of 2 quarters · filed 2023-03-29
-$2.07M
derived: sum of 3 quarters · filed 2023-03-29
-$1.12M
10-K · filed 2023-03-29
2021-09-30-$2.69M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
-$1.70M
derived: sum of 2 quarters · filed 2022-11-07
-$742.00K
10-Q · filed 2022-11-07
-$236.00K
derived: sum of 4 quarters · filed 2022-11-07
2021-06-30$990.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$1.94M
10-Q · filed 2022-08-04
$2.45M
derived: sum of 3 quarters · filed 2022-08-04
$2.09M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31$953.00K
10-Q · filed 2022-05-05
$1.46M
derived: sum of 2 quarters · filed 2022-05-05
$1.10M
derived: sum of 3 quarters · filed 2022-05-05
$935.00K
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31$506.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02
$146.00K
derived: sum of 2 quarters · filed 2022-03-02
-$18.00K
derived: sum of 3 quarters · filed 2022-03-02
$678.00K
10-K · filed 2022-03-02
$678.10K
10-K · filed 2021-03-08
2020-09-30-$360.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
-$524.00K
derived: sum of 2 quarters · filed 2021-11-09
$172.00K
10-Q · filed 2021-11-09
$171.90K
10-Q · filed 2020-11-09
-$3.28M
derived: sum of 4 quarters · filed 2021-11-09
2020-06-30-$164.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02
$532.00K
10-Q · filed 2021-08-02
$532.46K
10-Q · filed 2020-08-06
-$2.92M
derived: sum of 3 quarters · filed 2021-08-02
-$829.07K
derived: sum of 4 quarters · filed 2021-08-02
2020-03-31$696.00K
10-Q · filed 2021-05-13
$695.76K
10-Q · filed 2020-05-07
-$2.76M
derived: sum of 2 quarters · filed 2021-05-13
-$665.07K
derived: sum of 3 quarters · filed 2021-05-13
-$523.17K
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$3.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08
-$1.36M
derived: sum of 2 quarters · filed 2021-03-08
-$1.22M
derived: sum of 3 quarters · filed 2021-03-08
-$1.66M
10-K · filed 2021-03-08
2019-09-30$2.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$2.24M
derived: sum of 2 quarters · filed 2020-11-09
$1.80M
10-Q · filed 2020-11-09
$1.95M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30$141.89K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$297.27K
10-Q · filed 2020-08-06
-$148.25K
derived: sum of 3 quarters · filed 2020-08-06
-$448.04K
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31-$439.16K
10-Q · filed 2020-05-07
-$290.14K
derived: sum of 2 quarters · filed 2020-05-07
-$589.93K
derived: sum of 3 quarters · filed 2020-05-07
-$111.96K
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31$149.02K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11
-$150.77K
derived: sum of 2 quarters · filed 2020-03-11
$327.20K
derived: sum of 3 quarters · filed 2020-03-11
$222.53K
10-K · filed 2020-03-11
2018-09-30-$299.79K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14
$178.18K
derived: sum of 2 quarters · filed 2019-11-14
$73.51K
10-Q · filed 2019-11-14
$320.71K
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30$477.97K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
$373.30K
10-Q · filed 2019-08-08
$620.49K
derived: sum of 3 quarters · filed 2019-08-08
$620.49K
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31-$104.67K
10-Q · filed 2019-05-09
$142.52K
derived: sum of 2 quarters · filed 2019-05-09
$142.52K
derived: sum of 3 quarters · filed 2019-05-09
$142.52K
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$247.19K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
$247.19K
derived: sum of 2 quarters · filed 2019-03-18
$247.19K
derived: sum of 3 quarters · filed 2019-03-18
$247.19K
10-K · filed 2019-03-18
2017-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
$0.00
derived: sum of 2 quarters · filed 2018-11-13
$0.00
10-Q · filed 2018-11-13
2017-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$0.00
10-Q · filed 2018-08-09
2017-03-31$0.00
10-Q · filed 2018-05-11
2016-12-31$132.47K
10-K · filed 2018-04-02
2015-12-31$0.00
10-K · filed 2018-04-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
ARDELYX, INC. (ARDX)United States$0.857B-22.86
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
GERON CORP (GERN)United States$0.803B-12.14
Cryoport, Inc. (CYRX)United States$0.881B-21.29
Theravance Biopharma, Inc. (TBPH)$0.885B16.40
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25